Pivotal to collaborate with Checkpoint Therapeutics on a study in patients with cutaneous squamous cell carcinoma
- Global trial has recently expanded to Western Europe with the first European sites now initiated
- Collaboration will enable patients in Europe to access PD-L1 inhibitor to treat cSCC not...